The first was that PML or RARA mutation impaired the binding of PML-RARA to ATO or ATRA, respectively; the second was that additional gene mutations, especially FLT3-ITD/TKD mutation, cooperated with PML-RARA to drive APL progression. Here, RARA is linked to acute promyelocytic leukemia.